Randomized Phase II Trial of Ridaforolimus in Advanced Endometrial Carcinoma
Authors:
- Amit M. OzaAOAmit M. Oza
- Sandro PignataSPSandro Pignata
- Andres PovedaAPAndres Poveda
- Mary McCormackMMMary McCormack
- Andrew ClampACAndrew Clamp
- Benjamin SchwartzBSBenjamin Schwartz
- Jonathan ChengJCJonathan Cheng
- Xiaoyun LiXLXiaoyun Li
- Kristy CampbellKCKristy Campbell
- Pierre DodionPDPierre Dodion
- Frank G. HaluskaFHFrank G. Haluska
- 1 November 2015
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 33 (31) , 3576-3582
Abstract
Purpose: The prognosis for women with recurrent and metastatic endometrial cancer is poor, and improved therapies are needed. The mammalian target of rapamycin (mTOR) pathway is an important target, and mTOR inhibitors show clinical activity in endometrial cancer. Patients and Methods: An open-label, multicenter, randomized, phase II trial of oral ridaforolimus compared with progestin or investigator choice chemotherapy (comparator) was undertaken in women with metastatic or recurrent endometrial cancer who had progressive disease following one or two lines of chemotherapy and no hormonal therapy. The primary end point was progression-free survival (PFS) assessed by independent radiologic review. Results: One hundred thirty patients were enrolled (64 received ridaforolimus and 66 received the comparator), and median age was 66 years. Treatment discontinuation as a result of adverse events was 33% with ridaforolimus versus 6% with the comparator, with common (> 10%) grade 3 toxicities being hyperglycemia, anemia, and diarrhea. Thirty-eight percent (ridaforolimus) versus 71% (comparator) of patients discontinued treatment as a result of disease progression. Median PFS at the protocol prespecified interim analysis with 58 PFS events (primary end point) was 3.6 months (95% CI, 2.7 to 7.3 months) for ridaforolimus and 1.9 months (95% CI, 1.9 to 2.3 months) for the comparator (hazard ratio, 0.53; 95% CI, 0.31 to 0.90; P = .008). PFS rate for ridaforolimus versus comparator was 48% versus 18% at 16 weeks and 38% versus 15% at 24 weeks. Objective response rate for ridaforolimus versus comparator was 0% versus 4% (P = .925), and stable disease was achieved in 35% versus 17% of patients (P = .021). Conclusion: Oral ridaforolimus shows encouraging activity in advanced endometrial cancer but is associated with significant toxicity. Inhibition of the PI3K/Akt/mTOR pathway may be a viable therapeutic target.Keywords
This publication has 23 references indexed in Scilit:
- Molecular Characteristics and Risk Factors in Endometrial CancerInternational Journal of Gynecological Cancer, 2010
- Treatment options for advanced endometrial carcinomaGynecologic Oncology, 2010
- mTOR signaling and drug development in cancerNature Reviews Clinical Oncology, 2010
- Systemic therapy for recurrent endometrial cancer: a review of North American trialsExpert Review of Anticancer Therapy, 2009
- Systemic Chemotherapy for Uterine Carcinoma: Metastatic and AdjuvantJournal of Clinical Oncology, 2007
- Systemic therapy in metastatic or recurrent endometrial cancerCancer Treatment Reviews, 2007
- Endometrial CarcinomaAnnual Review of Pathology: Mechanisms of Disease, 2007
- Molecular and Pathologic Aspects of Endometrial CarcinogenesisJournal of Clinical Oncology, 2006
- Randomized Phase III Trial of Whole-Abdominal Irradiation Versus Doxorubicin and Cisplatin Chemotherapy in Advanced Endometrial Carcinoma: A Gynecologic Oncology Group StudyJournal of Clinical Oncology, 2006
- Two pathogenetic types of endometrial carcinomaGynecologic Oncology, 1983